News Release

Three poster presentations to be featured at the 66th Annual Meeting of the American Rhinologic Society

WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that the company will make presentations related to its lead product candidate, LYR-210, at the 66^th Annual Meeting of the American Rhinologic Society (ARS), taking place as a virtual event on September 10 and 12, 2020.

Three poster presentations related to LYR-210 for the treatment of chronic rhinosinusitis (CRS) will be featured in the virtual ARS annual meeting, with e-posters available during and after the conference, including on Lyra’s website. The posters presented by Lyra and collaborators include:

Poster: A novel continuous topical steroid implant (LYR-210) reduces sinonasal type 2 inflammation and rhinologic symptoms in chronic rhinosinusitis

• Co-Authors: Atsushi Kato, PhD, Aiko I. Klingler, PhD, Robert C. Kern, MD, and Robert P. Schleimer, PhD (all from Northwestern University Feinberg School of Medicine); Richard G. Douglas, MD (The University of Auckland, Auckland, New Zealand); Joanne Rimmer, MBBS, MA, FRCS (ORL-HNS), FRACS (Monash Health and Department of Surgery, Monash University, Melbourne, Australia); Alkis J. Psaltis, MBBS (HONS), PhD, FRACS (The Queen Elizabeth Hospital, Woodville South, South Australia); Tom Kuruvilla, MB ChB, FRACS (Christchurch Central, New Zealand); Anders Cervin, MD, PhD, FRACS (University of Queensland Centre for Clinical Research, Queensland, Australia); Yina Kuang, PhD (Lyra Therapeutics, Inc.)

Poster: Continuous steroid delivery by LYR-210 improves symptoms of chronic rhinosinusitis

• Co-Authors: Yina Kuang, PhD (Lyra Therapeutics, Inc.); Richard G. Douglas, MD (The University of Auckland, Auckland, New Zealand); Tom Kuruvilla, MB ChB, FRACS (Christchurch Central, New Zealand); Anders Cervin, MD, PhD, FRACS (University of Queensland Centre for Clinical Research, Queensland, Australia); Joanne Rimmer, MBBS, MA, FRCS (ORL‑HNS), FRACS (Monash Health and Department of Surgery, Monash University, Melbourne, Australia)

Poster: A drug release and pharmacokinetic evaluation of novel mometasone furoate eluting matrices

• Co-Authors from Lyra Therapeutics, Inc.: Changcheng You, PhD; Ling-Fang Tseng, PhD; Alex Pappas, PhD; Danny Concagh, MS; Yina Kuang, PhD

About Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. The company is advancing LYR-210 as a potential preferred alternative to surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed medical management. In its Phase 1 clinical trial, LYR-210 met its primary safety endpoint, and it was observed that patients generally experienced significant and rapid, clinically meaningful and durable improvement in SNOT-22 scores, an established patient symptom severity scale, through week 25, which was the end of the trial. The company is also developing LYR-220 for use in CRS patients who have an enlarged nasal cavity due to sinus surgery but continue to require treatment to manage CRS symptoms. Beyond CRS, the company believes its XTreo™ platform has potential applications in other disease areas, which it is actively exploring to further broaden the platform’s therapeutic potential.

For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company’s lead product candidate LYR-210.    These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the company has incurred significant losses since inception and expects to incur losses for the foreseeable future; the company’s need for additional funding, which may not be available; the company’s limited operating history; the fact that the company has no approved products; the fact that the company’s product candidates are in various stages of development; the fact that the company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the company’s product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the company’s product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the company’s inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the company’s product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the company’s reliance on third parties to conduct its preclinical studies and clinical trials; the company’s inability to succeed in establishing and maintaining collaborative relationships; the company’s reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the company’s intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the company’s growth; effects of natural disasters; the fact that the global pandemic caused by COVID-19 could adversely impact the company’s business and operations, including the company’s clinical trials; the fact that the price of the company’s common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation.  These and other important factors discussed under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2020 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

Media Contact:
Kathryn Morris
Tel: 914-204-6412
kathryn@theyatesnetwork.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@gilmartinir.com